Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues

Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues
ntaylor
Fri, 12/01/2023 – 07:57
Click here to view original post